Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Dermata Therapeutics, Inc., a late-stage medical dermatology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. The company's lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe acne; and Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis, as well as is in a Phase 2 clinical trial for treatment of moderate-to-severe rosacea. It is also developing DMT410 that has completed Phase Ib POC trials for the treatment of anxillary hyperhidrosis and aesthetic conditions. Dermata Therapeutics, Inc. was incorporated in 2014 and is headquartered in San Diego, California. more
Time Frame | DRMA | Sector | S&P500 |
---|---|---|---|
1-Week Return | 5.88% | 0.31% | -1.26% |
1-Month Return | 34.58% | 0.6% | -4.16% |
3-Month Return | 11.63% | -9.44% | -0.46% |
6-Month Return | -34.25% | -5.15% | 3.58% |
1-Year Return | -78.81% | 0.33% | 22.47% |
3-Year Return | -99.61% | 4.53% | 25.13% |
5-Year Return | -99.88% | 35.98% | 77.7% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Cost of Revenue | 1.35K | 322.00 | - | - | - | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":23.76,"profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Gross Profit | (1.35K) | (322.00) | - | - | - | [{"date":"2019-12-31","value":-135500,"profit":false},{"date":"2020-12-31","value":-32200,"profit":false},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Gross Margin | (Infinity%) | (Infinity%) | - | - | - | [{"date":"2019-12-31","value":null,"profit":false},{"date":"2020-12-31","value":null,"profit":false},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Operating Expenses | 4.47M | 3.17M | 7.86M | 9.67M | 8.04M | [{"date":"2019-12-31","value":46.21,"profit":true},{"date":"2020-12-31","value":32.8,"profit":true},{"date":"2021-12-31","value":81.21,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":83.12,"profit":true}] |
Operating Income | (4.47M) | (3.17M) | (7.86M) | (9.67M) | (8.04M) | [{"date":"2019-12-31","value":-447060800,"profit":false},{"date":"2020-12-31","value":-317285300,"profit":false},{"date":"2021-12-31","value":-785686400,"profit":false},{"date":"2022-12-31","value":-967448600,"profit":false},{"date":"2023-12-31","value":-804190600,"profit":false}] |
Total Non-Operating Income/Expense | (501.50K) | (260.95K) | (91.23K) | 127.15K | 450.66K | [{"date":"2019-12-31","value":-111.28,"profit":false},{"date":"2020-12-31","value":-57.9,"profit":false},{"date":"2021-12-31","value":-20.24,"profit":false},{"date":"2022-12-31","value":28.21,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Pre-Tax Income | (4.72M) | (3.24M) | (7.90M) | (9.61M) | (7.79M) | [{"date":"2019-12-31","value":-472135600,"profit":false},{"date":"2020-12-31","value":-323653000,"profit":false},{"date":"2021-12-31","value":-790247700,"profit":false},{"date":"2022-12-31","value":-961091300,"profit":false},{"date":"2023-12-31","value":-779469000,"profit":false}] |
Income Taxes | 250.75K | 197.27K | 45.61K | (9.67K) | (8.04K) | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":78.67,"profit":true},{"date":"2021-12-31","value":18.19,"profit":true},{"date":"2022-12-31","value":-3.86,"profit":false},{"date":"2023-12-31","value":-3.21,"profit":false}] |
Income After Taxes | (4.97M) | (3.43M) | (7.95M) | (9.60M) | (7.79M) | [{"date":"2019-12-31","value":-497210400,"profit":false},{"date":"2020-12-31","value":-343379900,"profit":false},{"date":"2021-12-31","value":-794809000,"profit":false},{"date":"2022-12-31","value":-960123851,"profit":false},{"date":"2023-12-31","value":-778664809,"profit":false}] |
Income From Continuous Operations | (4.72M) | (3.24M) | (7.90M) | (9.61M) | (7.33M) | [{"date":"2019-12-31","value":-472135600,"profit":false},{"date":"2020-12-31","value":-323653000,"profit":false},{"date":"2021-12-31","value":-790247700,"profit":false},{"date":"2022-12-31","value":-961091300,"profit":false},{"date":"2023-12-31","value":-733031900,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (4.97M) | (3.43M) | (7.95M) | (9.61M) | (7.79M) | [{"date":"2019-12-31","value":-497210400,"profit":false},{"date":"2020-12-31","value":-343379900,"profit":false},{"date":"2021-12-31","value":-794809000,"profit":false},{"date":"2022-12-31","value":-961091300,"profit":false},{"date":"2023-12-31","value":-779469000,"profit":false}] |
EPS (Diluted) | (0.74) | (1.21) | (29.12) | (14.72) | (3.65) | [{"date":"2019-12-31","value":-74.37,"profit":false},{"date":"2020-12-31","value":-120.61,"profit":false},{"date":"2021-12-31","value":-2912,"profit":false},{"date":"2022-12-31","value":-1472,"profit":false},{"date":"2023-12-31","value":-365,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
DRMA | |
---|---|
Cash Ratio | 3.16 |
Current Ratio | 3.44 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
DRMA | |
---|---|
ROA (LTM) | -90.68% |
ROE (LTM) | -173.01% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
DRMA | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.29 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.71 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
DRMA | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 0.00 |
P/B | 0.62 |
Price/FCF | NM |
EV/R | 0.00 |
EV/Ebitda | 0.58 |
Dermata Therapeutics Inc (DRMA) share price today is $1.44
Yes, Indians can buy shares of Dermata Therapeutics Inc (DRMA) on Vested. To buy Dermata Therapeutics Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in DRMA stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Dermata Therapeutics Inc (DRMA) via the Vested app. You can start investing in Dermata Therapeutics Inc (DRMA) with a minimum investment of $1.
You can invest in shares of Dermata Therapeutics Inc (DRMA) via Vested in three simple steps:
The 52-week high price of Dermata Therapeutics Inc (DRMA) is $8.65. The 52-week low price of Dermata Therapeutics Inc (DRMA) is $1.
The price-to-earnings (P/E) ratio of Dermata Therapeutics Inc (DRMA) is
The price-to-book (P/B) ratio of Dermata Therapeutics Inc (DRMA) is 0.62
The dividend yield of Dermata Therapeutics Inc (DRMA) is 0.00%
The market capitalization of Dermata Therapeutics Inc (DRMA) is $2.94M
The stock symbol (or ticker) of Dermata Therapeutics Inc is DRMA